In particular, statins, such as fluvastatin and atorvastatin, have demonstrated a reduction in mortality risk, decreased CRP levels, and a substantial improvement in endothelial function among COPD patients, as shown in the RODEO trial (NCT00929734), which highlighted endothelial improvements through FMD (63, 64). This evidence concerns the gene CRP and chronic obstructive pulmonary disease.